ACADIA (NASDAQ: ACAD) director Jonathan Poole submits initial Form 3 insider report

Rhea-AI Filing Summary

ACADIA PHARMACEUTICALS INC director Jonathan Poole filed an initial ownership report on Form 3. This filing establishes his status as a director and brings his holdings under the SEC's insider reporting framework, but it does not report any share purchases, sales, or other transactions.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Poole Jonathan

(Last) (First) (Middle)

C/O ACADIA PHARMACEUTICALS INC.

12830 EL CAMINO REAL, SUITE 400

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/03/2026

3. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Jennifer J. Rhodes, Attorney-in-Fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Jonathan Poole's Form 3 filing mean for ACAD (ACADIA PHARMACEUTICALS INC)?

It shows director Jonathan Poole has become a reportable insider under SEC rules. Form 3 is an initial ownership statement and does not itself indicate any recent stock purchases, sales, or changes in ACAD share ownership.

Does Jonathan Poole’s Form 3 show any ACAD share purchases or sales?

No, this Form 3 does not list any transactions in ACAD shares. It is an initial beneficial ownership filing, and the transaction summary shows zero buys, zero sells, and no derivative exercises or other activity.

What insider role does Jonathan Poole have at ACADIA PHARMACEUTICALS INC (ACAD)?

He is identified as a director of ACADIA PHARMACEUTICALS INC. The filing indicates director status only, with no officer title and no indication that he is a ten percent owner of ACAD common stock.

Are there any derivative securities reported for Jonathan Poole in this ACAD Form 3?

No derivative securities are reported for him in this Form 3. The derivative summary section is empty, and the transaction summary shows zero derivative transactions or option exercises related to ACAD securities.

Does the Form 3 for ACAD’s Jonathan Poole mention any Rule 10b5-1 trading plan?

No, the provided Form 3 details do not reference any Rule 10b5-1 trading plan. The footnote section contains no such disclosure and the transaction summary shows no trades to which a plan would apply.